Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MISAKO NAGASAKA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1063707958
CMS profile
1390221
Location
ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$119,923.27

109 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MISAKO NAGASAKA

NPI 1063707958 · CMS profile ID 1390221

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063707958?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MISAKO NAGASAKA, NPI 1063707958, CMS profile ID 1390221. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063707958?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MISAKO NAGASAKA, NPI 1063707958, CMS profile ID 1390221. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063707958?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MISAKO NAGASAKA, NPI 1063707958, CMS profile ID 1390221, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1063707958?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

109 matching records · $119,923.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 109 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–109 of 109.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Global Services, LLC $159.7502/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077590519 CMS
Regeneron Healthcare Solutions, Inc. $52.0802/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114121501 CMS
Regeneron Healthcare Solutions, Inc. $20.0402/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114121503 CMS
AstraZeneca Pharmaceuticals LP $2,740.0002/02/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104584826 CMS
E.R. Squibb & Sons, L.L.C. $1,300.0001/25/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101286604 CMS
Janssen Biotech, Inc. $100.8101/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078315380 CMS
Janssen Biotech, Inc. $241.2501/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078315788 CMS
Boehringer Ingelheim International GmbH $833.3301/15/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117858957 CMS
AstraZeneca Pharmaceuticals LP $685.0001/09/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104482992 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $25,021.75 39
PY2020 $27,782.01 25
PY2021 $54,860.05 46
PY2022 $76,513.80 49
PY2023 $96,456.68 97
PY2024 $119,923.27 109
PY2025 $106,175.03 97

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,929,743.35 84
PY2024 Recipient $19,703.32 2
PY2024 Principal investigator $1,058,712.92 69
PY2023 Principal investigator $703,392.40 48
PY2022 Principal investigator $359,817.00 16
PY2021 Recipient $749.32 1
PY2021 Principal investigator $768,456.39 104
PY2020 Recipient $747.74 2
PY2020 Principal investigator $1,300,906.82 400
PY2019 Principal investigator $793,187.83 178

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

84 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $10,428.00 12/25/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After Osimertinib Failure No dispute reported 06/30/2026 1175441675
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $69,164.21 12/23/2025 Covered Recipient Teaching Hospital
Uci Medical Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796465
Principal investigator 1 Daiichi Sankyo Inc. $11,880.00 12/18/2025 Covered Recipient Teaching Hospital
Uci Medical Center
U31402-A-U201 No dispute reported 06/30/2026 1223352388
Principal investigator 1 Daiichi Sankyo Inc. $42,886.05 12/18/2025 Covered Recipient Teaching Hospital
Uci Medical Center
U31402-A-U201 No dispute reported 06/30/2026 1223352390
Principal investigator 1 BeOne Medicines USA, Inc. $13,877.00 12/16/2025 Covered Recipient Teaching Hospital
Uci Medical Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190336007
Principal investigator 1 Janssen Research & Development, LLC $34,759.02 12/15/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175441776
Principal investigator 1 Janssen Research & Development, LLC $1,403.52 12/12/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions No dispute reported 06/30/2026 1175441557
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 12/01/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577508
Principal investigator 1 Boehringer Ingelheim Espana S.A. $71.84 12/01/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577510
Principal investigator 1 Boehringer Ingelheim Espana S.A. $41.95 12/01/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577512
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $61,395.64 11/30/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995236
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $184,186.92 11/30/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995238
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $263.70 11/19/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995240
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $174.90 11/19/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995242
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $59.94 11/19/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995244
Principal investigator 1 BeOne Medicines USA, Inc. $15,828.00 11/18/2025 Covered Recipient Teaching Hospital
Uci Medical Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190336003
Principal investigator 1 BeOne Medicines USA, Inc. $16,190.00 11/18/2025 Covered Recipient Teaching Hospital
Uci Medical Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190336011
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,982.72 11/11/2025 Covered Recipient Teaching Hospital
Uci Medical Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796463
Principal investigator 1 Janssen Research & Development, LLC $32,236.00 11/10/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175441787
Principal investigator 1 Janssen Research & Development, LLC $3,476.00 11/07/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After Osimertinib Failure No dispute reported 06/30/2026 1175441904
Principal investigator 1 Daiichi Sankyo Inc. $18,222.12 11/06/2025 Covered Recipient Teaching Hospital
Uci Medical Center
U31402-A-U201 No dispute reported 06/30/2026 1223352386
Principal investigator 1 Janssen Research & Development, LLC $13,936.00 11/06/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions No dispute reported 06/30/2026 1175441814
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 11/01/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577506
Principal investigator 1 Janssen Research & Development, LLC $12,616.92 10/23/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175441388
Principal investigator 1 Janssen Research & Development, LLC $1,403.52 10/23/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions No dispute reported 06/30/2026 1175441400
Principal investigator 1 Janssen Research & Development, LLC $20,442.32 10/23/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175441579
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 10/01/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577502
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 10/01/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577504
Principal investigator 1 Janssen Research & Development, LLC $6,952.00 09/29/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175441875
Principal investigator 1 Janssen Research & Development, LLC $23,505.13 09/22/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175441365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,990.00 09/18/2025 Covered Recipient Teaching Hospital
FOUNTAIN VALLEY REG MEDICAL CENTER
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184127248
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,105.76 09/18/2025 Covered Recipient Teaching Hospital
FOUNTAIN VALLEY REG MEDICAL CENTER
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184127250
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,620.00 09/18/2025 Covered Recipient Teaching Hospital
FOUNTAIN VALLEY REG MEDICAL CENTER
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184127252
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,670.92 09/18/2025 Covered Recipient Teaching Hospital
FOUNTAIN VALLEY REG MEDICAL CENTER
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184127254
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,795.00 09/18/2025 Covered Recipient Teaching Hospital
FOUNTAIN VALLEY REG MEDICAL CENTER
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184127256
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 09/01/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577500
Principal investigator 1 Janssen Research & Development, LLC $3,476.00 08/29/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175441899
Principal investigator 1 BeOne Medicines USA, Inc. $36,617.00 08/26/2025 Covered Recipient Teaching Hospital
Uci Medical Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190328363
Principal investigator 1 BeOne Medicines USA, Inc. $29,977.00 08/26/2025 Covered Recipient Teaching Hospital
Uci Medical Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190328365
Principal investigator 1 Janssen Research & Development, LLC $23,505.13 08/20/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175441798
Principal investigator 1 Janssen Research & Development, LLC $1,403.52 08/20/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions No dispute reported 06/30/2026 1175441917
Principal investigator 1 Janssen Research & Development, LLC $6,952.00 08/11/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175441435
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 08/01/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577498
Principal investigator 1 Partner Therapeutics, Inc. $21,256.00 07/30/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) No dispute reported 06/30/2026 1215516386
Principal investigator 1 Janssen Research & Development, LLC $22,490.09 07/24/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175441942
Principal investigator 1 Blueprint Medicines Corporation $15,732.00 07/04/2025 Covered Recipient Teaching Hospital
Uci Medical Center
BLU-945-1101 No dispute reported 06/30/2026 1235784397
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 07/01/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577496
Principal investigator 1 Janssen Research & Development, LLC $3,476.00 06/26/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175441532
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $81.62 06/24/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995232
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $26.60 06/24/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995234
Principal investigator 1 Janssen Research & Development, LLC $23,505.13 06/23/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175441741
Principal investigator 1 Janssen Research & Development, LLC $1,403.52 06/20/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions No dispute reported 06/30/2026 1175441304
Principal investigator 1 Janssen Research & Development, LLC $12,697.35 06/16/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175441441
Principal investigator 1 Janssen Research & Development, LLC $13,904.00 06/09/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175441887
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $14,645.00 06/03/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase II Open Label Randomized Study of MORAb-202 (farletuzumab ecteribulin, an antibody drug conjugate) in participants with metastatic non-small cell lung cancer (NSCLC) adenocarcinoma after progression on prior therapies. No dispute reported 06/30/2026 1235999998
Principal investigator 1 Janssen Research & Development, LLC $20,297.00 06/02/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175441857
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 06/01/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577494
Principal investigator 1 Janssen Research & Development, LLC $22,490.09 05/22/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175441866
Principal investigator 1 Janssen Research & Development, LLC $12,858.00 05/12/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175441793
Principal investigator 1 AstraZeneca Pharmaceuticals LP $98,592.91 05/07/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2 positive) (DESTINY-Lung03). No dispute reported 06/30/2026 1185540685
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 05/01/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577492
Principal investigator 1 Janssen Research & Development, LLC $34,432.95 04/25/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175441893
Principal investigator 1 Janssen Research & Development, LLC $20,442.32 04/18/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175441770
Principal investigator 1 BeOne Medicines USA, Inc. $5,640.00 04/17/2025 Covered Recipient Teaching Hospital
Uci Medical Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190326402
Principal investigator 1 BeOne Medicines USA, Inc. $12,480.00 04/17/2025 Covered Recipient Teaching Hospital
Uci Medical Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190338918
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $32,972.96 04/11/2025 Covered Recipient Teaching Hospital
Uci Medical Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796461
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 04/01/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577490
Principal investigator 1 Janssen Research & Development, LLC $3,476.00 03/31/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175441430
Principal investigator 1 AstraZeneca Pharmaceuticals LP $40,395.36 03/26/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase III Double-blind Randomised Placebo-Controlled International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage IA2-IA3 Non-small Cell Lung Cancer following Complete Tumour Resection No dispute reported 06/30/2026 1185540687
Principal investigator 1 Amgen Inc. $28,285.00 03/25/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Bemarituzumab Monotherapy and Combination With Other Anti-Cancer Therapy in Subjects With Squamous-Cell Non-Small-Cell Lung Cancer (FORTITUDE-201) No dispute reported 06/30/2026 1246638566
Principal investigator 1 Janssen Research & Development, LLC $15,331.74 03/20/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175441538
Principal investigator 1 Partner Therapeutics, Inc. $16,671.55 03/12/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) No dispute reported 06/30/2026 1215516761
Principal investigator 1 Eli Lilly and Company $3,947.80 03/07/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A PHASE 1/2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING RET FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER, AND OTHER TUMORS WITH RET ACTIVATION (LIBRETTO-001) No dispute reported 06/30/2026 1187871717
Principal investigator 1 Mirati Therapeutics, Inc. $168,444.93 03/03/2025 Non-covered Recipient Entity
Uci Health Fountain Valley
A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2 No dispute reported 06/30/2026 1236530471
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 03/01/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577486
Principal investigator 1 Janssen Research & Development, LLC $3,476.00 02/28/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175441610
Principal investigator 1 Janssen Research & Development, LLC $27,600.67 02/20/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175441573
Principal investigator 1 Partner Therapeutics, Inc. $13,958.00 02/05/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) No dispute reported 06/30/2026 1215516771
Principal investigator 1 Janssen Research & Development, LLC $10,428.00 02/03/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175441910
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 02/01/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577484
Principal investigator 1 AstraZeneca Pharmaceuticals LP $135,027.90 01/29/2025 Covered Recipient Teaching Hospital
Uci Medical Center
An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 or 20 mutation (DESTINY-Lung04) No dispute reported 06/30/2026 1185540689
Principal investigator 1 Janssen Research & Development, LLC $65,856.46 01/20/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175441973
Principal investigator 1 Eli Lilly and Company $236,406.60 01/02/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A PHASE 1A/1B STUDY OF LY3537982 IN PATIENTS WITH KRAS G12C-MUTANT ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1187877439
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 01/01/2025 Non-covered Recipient Entity
University Of California Irvine
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577488